{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:43:44Z","timestamp":1792215824286,"version":"4.4.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clinre.2026.102892","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:47:44Z","timestamp":1785253664000},"page":"102892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["From one-size-fits-all to on-demand: personalized crispr gene editing for rare genetic liver diseases"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2281-970X","authenticated-orcid":false,"given":"Anh Tuan","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2026.102892_bib0001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","article-title":"Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects","volume":"40","author":"Baruteau","year":"2017","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinre.2026.102892_bib0002","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/14712598.2016.1158808","article-title":"Gene editing technology as an approach to the treatment of liver diseases","volume":"16","author":"Aravalli","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clinre.2026.102892_bib0003","first-page":"852","article-title":"Rare but relevant: genetic liver disease in the general medical setting","volume":"55","author":"Schilsky","year":"2025","journal-title":"Intern Med J"},{"key":"10.1016\/j.clinre.2026.102892_bib0004","series-title":"Comprehensive genomic medicine","first-page":"345","article-title":"Liver diseases: genetic factors, current challenges, and future directions","author":"Parisi","year":"2024"},{"key":"10.1016\/j.clinre.2026.102892_bib0005","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.clinre.2026.102892_bib0006","doi-asserted-by":"crossref","DOI":"10.1126\/science.1258096","article-title":"The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.clinre.2026.102892_bib0007","unstructured":"US Food and Drug Administration. FDA approves first gene therapies to treat patients with sickle cell disease. FDA Press Release, December 8, 2023."},{"key":"10.1016\/j.clinre.2026.102892_bib0008","first-page":"1085","article-title":"Liver-directed gene therapy for inherited metabolic diseases","volume":"47","author":"Baruteau","year":"2024","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinre.2026.102892_bib0009","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0010","unstructured":"iECURE. Complete clinical response in first infant dosed with ECUR-506 in OTC deficiency. iECURE Press Release, January 2025."},{"key":"10.1016\/j.clinre.2026.102892_bib0011","unstructured":"UConn Today. World-first gene editing trial for rare genetic disease at UConn Health; 2025."},{"key":"10.1016\/j.clinre.2026.102892_bib0012","unstructured":"Children's Hospital of Philadelphia. World's first patient treated with personalized CRISPR gene editing therapy. CHOP News, February 2025."},{"key":"10.1016\/j.clinre.2026.102892_bib0013","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.clinre.2026.102892_bib0014","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2016.10.044","article-title":"CRISPR-based technologies for the manipulation of eukaryotic genomes","volume":"168","author":"Komor","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clinre.2026.102892_bib0015","first-page":"1381","article-title":"Cas9 activates the p53 pathway and selects for p53-inactivating mutations","volume":"50","author":"Enache","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinre.2026.102892_bib0016","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2026.102892_bib0017","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","article-title":"Base editing: precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.clinre.2026.102892_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32906-9","article-title":"In vivo adenine base editing reverts C282Y and improves iron metabolism in hemochromatosis mice","volume":"13","author":"Rovai","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinre.2026.102892_bib0019","first-page":"743","article-title":"VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9","volume":"17","author":"Gillies","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.clinre.2026.102892_bib0020","unstructured":"Beam Therapeutics. BEAM-301 preclinical data for glycogen storage disease type Ia. Beam Therapeutics Pipeline Update, 2024."},{"key":"10.1016\/j.clinre.2026.102892_bib0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2026.102892_bib0022","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41467-021-22295-w","article-title":"Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinre.2026.102892_bib0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","article-title":"Prime editing for precise and highly versatile genome manipulation","volume":"24","author":"Chen","year":"2023","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.clinre.2026.102892_bib0024","first-page":"1618","article-title":"Efficient prime editing in mouse brain, liver and heart with dual AAVs","volume":"41","author":"Zheng","year":"2023","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinre.2026.102892_bib0075","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2026.102892_bib0025","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing","volume":"184","author":"Nuez","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.clinre.2026.102892_bib0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","article-title":"CRISPR technologies for precise epigenome editing","volume":"23","author":"Nakamura","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.clinre.2026.102892_bib0027","first-page":"1234","article-title":"Programmable epigenome editing by transient delivery of CRISPR epigenome editor ribonucleoproteins","volume":"16","author":"Josipovic","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinre.2026.102892_bib0028","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202401632","article-title":"Lipid nanoparticles for delivery of CRISPR gene editing components","volume":"10","author":"Wu","year":"2026","journal-title":"Small Methods"},{"key":"10.1016\/j.clinre.2026.102892_bib0029","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinre.2026.102892_bib0030","first-page":"701","article-title":"Lipid-nanoparticle-based delivery of CRISPR\/Cas9 genome-editing components","volume":"19","author":"Rui","year":"2022","journal-title":"Mol Pharm"},{"key":"10.1016\/j.clinre.2026.102892_bib0031","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMoa2510209","article-title":"Nexiguran ziclumeran gene editing in hereditary ATTR with polyneuropathy","volume":"393","author":"Gillmore","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0032","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0033","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jimd.12637","article-title":"Liver-directed adeno-associated viral vectors to treat metabolic disease","volume":"47","author":"Chuecos","year":"2024","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinre.2026.102892_bib0034","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging issues in AAV-mediated in vivo gene therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.clinre.2026.102892_bib0035","first-page":"523","article-title":"AAV capsid prioritization in normal and steatotic human livers","volume":"42","author":"Zincarelli","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinre.2026.102892_bib0036","first-page":"1151","article-title":"Gene therapy for inborn errors of hepatocyte metabolism","volume":"78","author":"Baruteau","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2026.102892_bib0037","unstructured":"Drug Target Review. Advancing gene editing: the role of lipid nanoparticles in CRISPR delivery; 2024."},{"key":"10.1016\/j.clinre.2026.102892_bib0038","series-title":"Proceedings of the ASGCT annual meeting","article-title":"OTC-HOPE study interim data presentation","year":"2025"},{"key":"10.1016\/j.clinre.2026.102892_bib0039","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10545-014-9772-x","article-title":"Type I glycogen storage diseases: disorders of the glucose-6-phosphatase\/glucose-6-phosphate transporter complexes","volume":"38","author":"Chou","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clinre.2026.102892_bib0040","article-title":"Patient-specific in vivo gene editing to treat a rare genetic disease","volume":"392","author":"Gillmore","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0041","unstructured":"Verve Therapeutics. VERVE-102 trial positive initial data. Verve Therapeutics Press Release, April 2025."},{"key":"10.1016\/j.clinre.2026.102892_bib0043","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ymgme.2013.07.008","article-title":"The incidence of urea cycle disorders","volume":"110","author":"Summar","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.clinre.2026.102892_bib0044","first-page":"768","article-title":"Genetic and functional correction of argininosuccinate lyase deficiency using CRISPR adenine base editors","volume":"111","author":"Villiger","year":"2024","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinre.2026.102892_bib0045","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha-1 antitrypsin deficiency","volume":"382","author":"Strnad","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0042","unstructured":"CRISPR Therapeutics. CTX460 preclinical data for alpha-1 antitrypsin deficiency utilizing SyNTase editing platform. CRISPR Therapeutics Press Release, 2024."},{"key":"10.1016\/j.clinre.2026.102892_bib0046","unstructured":"Intellia Therapeutics. Intellia achieves normal human alpha-1 antitrypsin protein levels in non-human primates. Intellia Press Release, 2024."},{"key":"10.1016\/j.clinre.2026.102892_bib0047","first-page":"487","article-title":"Selection for somatic escape variants in SERPINA1 in alpha-1 antitrypsin deficiency","volume":"57","author":"Lurbe","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinre.2026.102892_bib0048","first-page":"55","article-title":"Wilson disease","volume":"10","author":"Schilsky","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clinre.2026.102892_bib0049","doi-asserted-by":"crossref","first-page":"9253","DOI":"10.1073\/pnas.1323941111","article-title":"Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs","volume":"111","author":"Park","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clinre.2026.102892_bib0050","article-title":"Production of Wilson disease model rabbits with homology-directed precision point mutations in the ATP7B gene using CRISPR\/Cas9","volume":"8","author":"Wooton-Kee","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinre.2026.102892_bib0051","first-page":"1321","article-title":"Expanding the spectrum of progressive familial intrahepatic cholestasis","volume":"80","author":"Amirneni","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2026.102892_bib0052","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cld.2018.06.003","article-title":"Progressive familial intrahepatic cholestasis","volume":"22","author":"Bull","year":"2018","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.clinre.2026.102892_bib0053","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13614-3","article-title":"Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model","volume":"10","author":"Weber","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinre.2026.102892_bib0054","unstructured":"FDA. FDA approves maralixibat tablets for cholestatic pruritus in Alagille syndrome. FDA Press Release, April 2025."},{"key":"10.1016\/j.clinre.2026.102892_bib0055","unstructured":"European Medicines Agency. Odevixibat approved for cholestatic pruritus. EMA Press Release, September 2024."},{"key":"10.1016\/j.clinre.2026.102892_bib0056","unstructured":"NICHD. Gene editing technique corrects glycogen storage disease type Ia in mouse model. NICHD News, February 2025."},{"key":"10.1016\/j.clinre.2026.102892_bib0057","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","article-title":"Porphyrias","volume":"375","author":"Puy","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinre.2026.102892_bib0058","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic Givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0059","unstructured":"CRISPR Therapeutics. CTX450 expected to begin first-in-human clinical trials in H2 2025. CRISPR Therapeutics Pipeline Update, 2024."},{"key":"10.1016\/j.clinre.2026.102892_bib0076","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1089\/hum.2013.233","article-title":"Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar syndrome","volume":"25","author":"Bortolussi","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.clinre.2026.102892_bib0077","first-page":"1456","article-title":"AAV-mediated gene replacement for Crigler-Najjar syndrome: preliminary results of a phase I\/II trial","volume":"32","author":"Porro","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinre.2026.102892_bib0078","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nbt.2884","article-title":"Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype","volume":"32","author":"Yin","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinre.2026.102892_bib0079","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1089\/hum.2017.252","article-title":"Curative ex vivo hepatocyte-directed gene editing in a mouse model of hereditary tyrosinemia type 1","volume":"29","author":"VanLith","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.clinre.2026.102892_bib0060","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinre.2026.102892_bib0061","first-page":"1129","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"383","author":"Garrelfs","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0062","first-page":"243","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"29","author":"Benson","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.clinre.2026.102892_bib0063","article-title":"Antisense oligonucleotides: a novel frontier in pharmacological strategy","volume":"14","author":"Dhuri","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinre.2026.102892_bib0064","first-page":"4157","article-title":"Delivering the message: translating mRNA therapy for liver inherited metabolic diseases","volume":"32","author":"Berraondo","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.clinre.2026.102892_bib0080","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clinre.2026.102892_bib0081","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0082","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","article-title":"Therapeutic in vivo delivery of gene editing agents","volume":"185","author":"Raguram","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.clinre.2026.102892_bib0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nbt.3117","article-title":"GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases","volume":"33","author":"Tsai","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinre.2026.102892_bib0066","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nmeth.3284","article-title":"Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells","volume":"12","author":"Kim","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.clinre.2026.102892_bib0067","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.clinre.2026.102892_bib0083","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41587-020-0414-6","article-title":"Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors","volume":"38","author":"Doman","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clinre.2026.102892_bib0084","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.clinre.2026.102892_bib0068","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0069","article-title":"Strategies to address Cas9 immunogenicity","volume":"73","author":"Li","year":"2024","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.clinre.2026.102892_bib0085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.clinre.2026.102892_bib0070","unstructured":"Food U.S and Administration D. Innovative designs for clinical trials of cellular and gene therapy products in small populations; draft guidance. Federal Register, September 2025."},{"key":"10.1016\/j.clinre.2026.102892_bib0071","unstructured":"BioPharma Dive. FDA unveils new regulatory roadmap for bespoke drug therapies; 2025."},{"key":"10.1016\/j.clinre.2026.102892_bib0072","unstructured":"European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. EMA\/CAT\/80183\/2014 Rev.1, 2024."},{"key":"10.1016\/j.clinre.2026.102892_bib0086","first-page":"241","article-title":"Platform-based regulatory approaches for bespoke gene therapies","volume":"24","author":"Batta","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinre.2026.102892_bib0073","unstructured":"TechTarget. The top 5 most expensive FDA-approved gene therapies; 2024."},{"key":"10.1016\/j.clinre.2026.102892_bib0074","first-page":"662","article-title":"Towards affordable CRISPR genomic therapies: a task force convened by the innovative genomics institute","volume":"30","year":"2023","journal-title":"Gene Ther"},{"key":"10.1016\/j.clinre.2026.102892_bib0087","first-page":"1035","article-title":"Analytic framework for assessing value of single- or limited-administration cell and gene therapies","volume":"26","author":"Drummond","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.clinre.2026.102892_bib0088","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.clinre.2026.102892_bib0089","unstructured":"World Health Organization. Human genome editing: a framework for governance. WHO Expert Advisory Committee Report, 2021."}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126001385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:17:39Z","timestamp":1792214259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126001385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":89,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2210740126001385"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102892","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From one-size-fits-all to on-demand: personalized crispr gene editing for rare genetic liver diseases","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102892"}}